EGFR and non-small cell lung carcinoma: Metabolic reprogramming driven by oncogenic alterations—particularly Epidermal Growth Factor Receptor (EGFR) mutations in non-small cell lung cancer (NSCLC)—creates distinctive plasma signatures with clinical relevance.